The head of the U.S. Food and Drug Administration says marijuana may offer meaningful therapeutic value for certain patients, even as federal officials continue to raise concerns about potential health risks — particularly among young users.
During a recent television interview, FDA Commissioner Marty Makary emphasized that the administration is balancing two priorities: recognizing cannabis’s medical usefulness while addressing safety issues tied to modern high-potency products. He pointed to rising rates of THC vaping among teenagers and said stronger cannabis formulations may have different effects on developing brains compared to those of adults. According to Makary, research suggests possible links between youth use and long-term outcomes such as psychosis, along with side effects including fatigue, learning impairment, and conditions like cannabis hyperemesis syndrome.
At the same time, he stressed that policymakers are not dismissing cannabis’s therapeutic role. Federal officials are working to maintain access for patients who benefit from medical marijuana, including individuals dealing with serious illnesses such as chronic or terminal cancer. That outlook is reflected in efforts to move marijuana from Schedule I to Schedule III under federal law — a change intended to acknowledge medical use while easing research and regulatory barriers.
The broader rescheduling process, initiated under a previous administration and pushed forward through executive action, remains unresolved. Federal agencies have indicated that legal and scientific reviews are still ongoing, and potential delays or procedural challenges could affect the timeline.
Makary has also cautioned about other cannabinoid products circulating in the marketplace, warning that certain compounds may carry risks such as cardiac complications or psychiatric effects. Meanwhile, the administration continues to signal interest in expanding scientific exploration of alternative therapies, including psychedelics, particularly in the context of mental health treatment for veterans.
The debate highlights a continuing tension in federal cannabis policy — one that recognizes potential medical benefits while grappling with public health concerns, evolving science, and shifting political priorities.
Dabbin-Dad Newsroom
